Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Biobanking Congress 2015, Toronto, InterContinental Toronto Centre, July 14-16, 2015

Reporter: Aviva Lev-Ari, PhD, RN

 

FINAL AGENDA

 

Cambridge Healthtech Institute’s Seventh International Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research.

KEYNOTE SESSION: IT TAKES A VILLAGE

The Complexity of Pathologist Responsibilities as Custodians of Biospecimens

Sylvia L. Asa, M.D., Ph.D., Pathologist-in-Chief, Medical Director, Laboratory Medicine Program, University Health Network; Lakeridge Health &

Women’s College Hospital; Senior Scientist, Ontario Cancer Institute; Professor, Laboratory Medicine & Pathobiology, University of Toronto

Discovery and Implementation Using EHR-Linked Biobanks: The eMERGE Experience

Rex L. Chisholm, Ph.D., Vice Dean, Scientific Affairs and Graduate Education; Adam and Richard T. Lind Professor, Medical Genetics, Northwestern

University Feinberg School of Medicine

Preparing Research Samples for Future Use: Innovative Methods for Assessing Functional Quality Control and Biobanking Best Practices

Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

Generating Comprehensive Standard Operating Procedures for a Biorepository Network – The CTRNet Experience

Brent Schacter, M.D., FRCPC, Principal Investigator, CTRNet; Professor, Department of Internal Medicine, Section of Hematology/

Oncology, College of Medicine, University of Manitoba/CancerCare Manitoba

MAINTAINING A QUALITY BIOBANK

Development and Implementation of a National Biospecimen Collection Network in a Community Hospital System

Jeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Inventory Management; Re-Organization, Consolidation, Quality Assurance and the Cost of Space in the Biorepository

Sherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women’s Hospital

Is There a Web-Based Solution to the Challenge of Informed Consent and Re-Consent of Legacy Biobank Samples?

Daniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Tissue Banking, Bioinformatics and EMRs: The Front-End Requirements for Personalized Medicine

K. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

PANEL DISCUSSION: Ensuring Biobank Value through Effective Utilization

Moderators:

Marianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for

Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER

Marianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of

Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

Panelists:

Jeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Sherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women’s Hospital

K. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Daniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Additional Panelists to be Announced

BIOSAMPLES, BIOMARKERS AND CLINICAL TRIALS

FEATURED PRESENTATION :

TRANSLATING PRECISION MEDICINE STRATEGY INTO OUTCOME THROUGH CLINICAL TRIALS

Lillian L. Siu, M.D., FRCPC, Professor, University of Toronto; Medical Oncologist, Princess Margaret Cancer Centre

Obtaining Biospecimens for Correlative Studies in Multi-Centre Lymphoma Clinical Trials

Koren Mann, Ph.D., Assistant Professor, Oncology, Lady Davis Institute for Medical Research, McGill University

Case Study #1: Biospecimen Sciences, Clinical Trials and Precision Medicine: Examples from Our Practice

Michael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

Anthony M. Joshua, MBBS, Ph.D., Staff Oncologist/Affiliate Scientist, Princess Margaret Cancer Centre

TOOLS TO ACCESS BIOSPECIMEN QUALITY

From Research to Clinic: (Pre-)Analytical Variables and Assay Development

Veronique Neumeister, M.D., Laboratory Director, Specialized Translational Services Lab, Department of Pathology, Yale University School of Medicine

Experimental Animal Models to Inform Human Biobanking Practices

Galen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute

Freezing under Pressure: A New Method for Cryopreservation

Nickolas Greer, CSO, Rissali LLC

Microfluidic Evaluation of Red Cells Collected and Stored in Modified Processing Solutions Used in Blood Banking

Dana Spence, Ph.D., Associate Professor, Department of Chemistry, Michigan State University

FEATURED PRESENTATION:

PRE-ANALYTICAL VARIABLES IMPACTING PERIPHERAL BLOOD SAMPLES FOR IMMUNE MONITORING IN MULTICENTER STUDIES

Amit Bar-Or, M.D., FRCPC, Professor, Neurology & Neurosurgery; Director, Experimental Therapeutics Program and Scientific Director, Clinical Research

Unit, Montreal Neurological Institute, McGill University

CASE STUDIES: BIOBANKER/BIOUSER PARTNERSHIPS

Biomedical researchers and drug developers require accessible, highquality biospecimens that allow them to extract reliable and useful data.

Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients

post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house

specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store,

annotate and distribute the biological samples (“biobankers”) and supporting the research goals of the scientists who need those samples

(“biousers”) – all to fulfill the promise of personalized medicine.

SPECIALTY BIOBANKS

The Future of iPSCs Biobanking

Jonathan Y.H. Loh, Ph.D., Assistant Professor, Department of Biological Sciences, National University of Singapore, A*STAR Institute of

Molecular and Cell Biology

Biobanking to Improve Cardiac Transplant Outcomes

Dawn E. Bowles, Ph.D., Assistant Professor, Department of Surgery, Division of Surgical Sciences and Co-Director, Duke Human Heart Repository

Planning and Implementing an Institutional Hospital for Children and Women: Ethical and Operational Consideration

Suzanne Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children’s Hospital and Clinical Assistant Professor,

Pathology and Laboratory Medicine, University of British Columbia

The University Health Network Genito-Urinary (GU) BioBank

Neil Fleshner, M.D., MPH, FRCSC, Chair, Urology, Department of Surgery, University of Toronto; Head, Urology, University Health Network; Director,

GU BioBank, Princess Margaret Cancer Centre

Give Life Twice – An Overview of Canada’s National Public Cord Blood Bank

Heidi Elmoazzen, Ph.D., Director, National Public Cord Blood Bank

Toronto Lung Transplant Biobanking Project, What We Are Collecting

Sassan M. Azad, Project Manager, Clinical, Translational & Biobanking Research Office, Toronto Lung Transplant Program, Toronto General Hospital,

University Health Network

MAINTAINING A QUALITY BIOBANK WITH IT

Progress Is Bringing Together Clinical and Biorepository Data in an Expandable Research Data Repository

Maureen E. Lane, Ph.D., Assistant Professor, Medicine; Director, Hem/Onc Translational Core Laboratory, The Leukemia Biorepository and Personalized

Medicine Center, Weill Cornell Medical College

Data Bank and BioRepository for Translational and Basic Research

Annmarie Nowak, Coordinator & Director, Data Bank and Biorepository, Biobanking Systems Integration Cancer Prevention and Population Science,

Roswell Park Cancer Institute

Promoting Quality Biobanks and Biobank Quality: The CRIP Toolbox and the Metabiobank p-BioSPRE

Christina Schröder, Ph.D., Head, Metabiobanks CRIP, Fraunhofer Institute for Cell Therapy and Immunology

Register by March 20th & Save!

For sponsorship and exhibit sales information, contact:

Carolyn Benton

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5412

Email: cbenton@healthtech.com

Healthtech.com/Biobanking

 

SOURCE

From: Leaders in Biobanking <kerris@healthtech.com>
Date: Fri, 06 Mar 2015 11:36:31 -0500
To: <avivalev-ari@alum.berkeley.edu>
Subject: Final Agenda Now Available